Literature DB >> 21445861

Allogeneic mesenchymal stem cells: agents of immune modulation.

Karen English1, Bernard P Mahon.   

Abstract

Adult mesenchymal stem cells possess a remarkably diverse array of immunosuppressive characteristics. The capacity to suppress the regular processes of allogeneic rejection, have allowed the use of tissue mismatched cells as therapeutic approaches in regenerative medicine and as agents of immune deviation. This review describes recent advances in understanding the mechanistic basis of mesenchymal stromal or stem cells (MSC) interaction with innate immunity. Particular emphasis is placed on the effect of Toll-like receptor signalling on MSC and a hypothesis that innate immune signals induce a 'licensing switch' in MSC is put forward. The mechanisms underlying MSC suppression of T cell responses and induction of regulatory populations are surveyed. Conflicting data regarding the influence of MSC on B cell function are outlined and discussed. Finally the limits to MSC mediated immune modulation are discussed with reference to the future clinical application of novel cell therapies.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445861     DOI: 10.1002/jcb.23119

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  51 in total

Review 1.  Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation.

Authors:  Darwin J Prockop; Joo Youn Oh
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

4.  Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.

Authors:  Ki-Wook Oh; Chanil Moon; Hyun Young Kim; Sung-Il Oh; Jinseok Park; Jun Ho Lee; In Young Chang; Kyung Suk Kim; Seung Hyun Kim
Journal:  Stem Cells Transl Med       Date:  2015-05-01       Impact factor: 6.940

5.  Mesenchymal stem cells are injured by complement after their contact with serum.

Authors:  Yan Li; Feng Lin
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

Review 6.  NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity.

Authors:  Javier G Casado; R Tarazona; F M Sanchez-Margallo
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

7.  Immunoevasive pericytes from human pluripotent stem cells preferentially modulate induction of allogeneic regulatory T cells.

Authors:  Hagit Domev; Irina Milkov; Joseph Itskovitz-Eldor; Ayelet Dar
Journal:  Stem Cells Transl Med       Date:  2014-09-09       Impact factor: 6.940

Review 8.  Would cancer stem cells affect the future investment in stem cell therapy.

Authors:  Pranela Rameshwar
Journal:  World J Exp Med       Date:  2012-04-20

9.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

10.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.